Clinical and genomic characteristics of hepatocellular carcinoma-cholangiocarcinoma: Insights from real-world data.
Oluseyi Abidoye(Mayo Clinic), Tanios Bekaii‐Saab(WinnMed), Taro Shibuki(National Cancer Center Hospital East), Mitesh J. Borad(Jacksonville College), Masafumi Ikeda(National Cancer Center Hospital East), Chigusa Morizane, Christina Wu(Mayo Clinic Hospital), Heidi Kosiorek(Mayo Clinic in Florida), Binbin Zheng-Lin(WinnMed), Hideaki Bando(Aichi Cancer Center), Cody Eslinger(WinnMed), Takao Fujisawa(National Cancer Center Hospital East), Mohamad Bassam Sonbol(WinnMed), Takayuki Yoshino(University of Tsukuba), Daniel H. Ahn(Mayo Clinic Hospital), Naohiro Okano(Kyorin University), Angelo Pirozzi, Isabela Chang(WinnMed), Celine Hoyek(Mayo Clinic Hospital), Yoshiaki Nakamura(National Cancer Center Hospital East)
Cited by 1
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k